2. Biphasic binding molecules, including DL4 or Dii4 and vascular membrane growth factor (VEGF)； Separated nucleic acid molecular coding； Vector； Clula Hugheside, Processing method； Composition； 1. Understanding the situation of drugs； the use of components in carcinogenic therapy； and VHH from aggregation to DL4.
BORGES ERIC,GSCHWIND ANDREAS,DE TAVERNIER EVELYN,KOLKMAN JOOST,MERCHIERS PASCAL,VAN HOORICK DIANE,BOUCNEAU JOACHIM
申请号：
CL2012000826
公开号：
CL2012000826A1
申请日:
2012.04.02
申请国别(地区):
CL
年份:
2012
代理人:
摘要：
Bispecific binding molecules, in particular immunoglobulin single variable domains such as VHHs and domain antibodies, comprising a VEGF-binding component and a Dll4-binding component in one molecule. Pharmaceutical compositions containing same and their use in the treatment of diseases that are associated with VEGF- and Dll4-mediated effects on angiogenesis. Nucleic acids encoding the bispecific binding molecules, host cells and methods for preparing same.MOLÉCULA DE UNIÓN BIESPECÍFICA QUE COMPRENDE UN COMPONENTE DE UNIÓN AL LIGANDO TIPO DELTA 4 (DLL4 O DII4) Y UN COMPONENTE DE UNIÓN AL FACTOR DE CRECIMIENTO ENDOTELIAL VASCULAR (VEGF)； MOLÉCULA DE ÁCIDO NUCLEICO AISLADA QUE LA CODIFICA； VECTOR； CÉLULA HUÉSPED, MÉTODO DE ELABORACIÓN； COMPOSICIÓN FARMACÉUTICA QUE LA COMPRENDE； USOS DE LA COMPOSICIÓN EN TRATAMIENTO DE CÁNCER； Y VHH DE UNIÓN A DLL4.
